| Prognostic factors in nonsmall cell lung cancer: insight from the German CRISP registry. |
|
|
| Eur Respir J. 61 (2): 2201336 |
|
2023 |
|
Thorakale Onkologie
|
|
|
| www.doi.org/10.1183/13993003.01336-2022 |
|
|
| s00066-023-02083-9 (poster P09-4jD DEGRO 2023) 3. Kasper, S., Stein, A., Kühl, C. et al. Perioperative/adjuvante Studie mit Atezolizumab mit oder ohne den Immunmodulator IMM-101 bei Patienten mit MSIhigh oder MMR-defizientem Kolorektalkarzinom im Stadium III, die ungeeignet für eine oxaliplatinbasierte Chemotherapie sind – eine randomisierte Phase-II-Studie – AIO-KRK-0220. |
|
|
| FORUM 38: 240-3 |
|
2023 |
|
Thorakale Onkologie
|
|
|
| www.doi.org/10.1007/s12312-023-01196-7 |
|
|
| PCI in der metastasierten Situation beim SCLC in real world: Daten aus der Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315). |
|
|
| Strahlenther Onkol 199 (Suppl 1): 97 |
|
2023 |
|
Thorakale Onkologie
|
|
|
| www.doi.org/10.1007/s00066-023-02083-9 |
|
|
| Real-world Daten zur Erhaltungstherapie mit Durvalumab nach definitiver Strahlenchemotherapie bei Patienten mit Nicht-Kleinzelligem Lungenkarzinom in lokal fortgeschrittenen Stadien: Daten aus der Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315) |
|
|
| Strahlenther Onkol 199 (Suppl 1): 103 |
|
2023 |
|
Thorakale Onkologie
|
|
|
| www.doi.org/10.1007/s00066-023-02083-9 |
|
|
| Prognostic factors in non-small-cell: insight from the German crisp registry. |
|
|
| Eur Respir J. 61 (2): 2201336 |
|
2023 |
|
Thorakale Onkologie
|
|
|
| erj.ersjournals.com/content/early/2022/09/14/13993003.01336-2022 |
|
|
| Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-smal cell lung cancer (NSCLC) - a modelling approach |
|
|
| J Cancer Res Clin Oncol. 149: 1495-1511 |
|
2023 |
|
Thorakale Onkologie
|
|
|
| link.springer.com/article/10.1007/s00432-022-04034-w |
|
|
| Leitlinienadhärenz bei Anämiemanagement, Neutropenie-Prophylaxe, Osteoprotektion, Immunglobulinsubstitution und Antiemese – repräsentative Studien der AIO und AGSMO |
|
|
| AGSMO Jahreskongress 2023 |
|
2023 |
|
Supportive Therapie
|
|
|
|
|
|
| Real World Data on Anemia Management in Patients with Solid Tumors and Malignant Lymphoma in Germany |
|
|
| AGSMO Jahreskongress 2023 |
|
2023 |
|
Supportive Therapie
|
|
|
|
|
|
| Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Quality of life results of the randomized phase II AIO-NEONAX trial. |
|
|
| J Clin Oncol 41 (suppl 4, abstr 694) |
Abstract |
2023 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1200/JCO.2023.41.4_suppl.694 |
|
|
| https://doi.org/10.1016/j.annonc.2023.09.2473 |
|
|
| 2023 |
|
2023 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1016/j.annonc.2023.09.2573 |
|
|
